Global Antibiotic R&D Partnership (GARDP)
Putting public health needs at the centre of antibiotic drug development to address the crisis of antimicrobial resistance (AMR).
gardp.org/this-is-big/
- 🧬A new #REVIVE viewpoint explores the ongoing challenges in treating carbapenem-resistant Acinetobacter baumannii, outlining where therapies fall short and what’s needed next to improve patient outcomes. 🔗 Read more: revive.gardp.org/managing-aci...
- 🎉🧬 That’s a wrap on #ACC2026 An incredible and a valuable space for the AMR community to connect, exchange evidence and reflect on what comes next. Thank you all for the energy and ideas. See you next year! 🔗Register to watch the recorded sessions and more: acc-conference.com#registration
- 🔴🚨 FINAL SESSION IS LIVE at #ACC2026 Title: Access isn’t the end, it’s the beginning. Our closing panel takes on the purpose of antimicrobial innovation, and what must come after access. 🔴 WATCH IT LIVE NOW: portalapp.bsac.eventsair.com/VirtualAtten...
- 🔴🚨 Happening LIVE right now From womb to world, this session tackles one of the most urgent gaps in AMR: how we design, test and deliver antimicrobials for pregnant women, newborns and children. 🔗Tune in live now: portalapp.bsac.eventsair.com/VirtualAtten... #ACC2026
- 🪧Now live | Session Six at #ACC2026 This session features rapid-fire oral poster presentations highlighting emerging data and new insights across antimicrobial resistance and infectious diseases research. 👉 Watch live: portalapp.bsac.eventsair.com/VirtualAtten...
- 🚀🔬Day 2 kicks off with Session Five at #ACC2026 Clinical development and use of new agents takes centre stage as we dive into how emerging treatments move from trials to practice. 🎥 Join us live now: portalapp.bsac.eventsair.com/VirtualAtten... @gsk.bsky.social #AMR #ClinicalDevelopment
- 🏁✨Final day of #ACC2026 Starting off with Introductory remarks from Dr François Franceschi of GARDP. One last round of sessions, discussions and shared learning as the conference draws to a close. ✊Let’s finish strong! 🔴🔗Join us live here: portalapp.bsac.eventsair.com/VirtualAtten...
- ✨ Day 1 of #ACC2026 wrapped up strong! From research to real-world practice, today’s sessions delivered strong science, open dialogue and a clear sense of shared purpose across the AMR community. ⏳Missed Day 1? You can still register and join us for Day 2. 🔗 acc-conference.com#registration
- 🔴#ACC2026 Day 1 I We’re live with today's final session Equitable TB care is in focus as experts tackle the treatment gaps facing vulnerable populations. Experts from across Asia are discussing solutions right now. 🔗Join them: portalapp.bsac.eventsair.com/VirtualAtten... @lshtm.bsky.social
- 📣🌏Up next at #ACC2026 A dynamic panel with experts from Singapore, Taiwan and Thailand discussing - future TB therapies - TB in pregnancy & childhood - tackling MDR-TB in LMICs 🔗Be part of the discussion live: portalapp.bsac.eventsair.com/VirtualAtten...
- 3⃣🚀Session Three has just started at #ACC2026 The focus turns to preclinical antimicrobial development, with talks exploring lysin biotherapeutics, anti-virulence approaches and new adjunct therapies to tackle drug-resistant infections. 🎥 Join us now: portalapp.bsac.eventsair.com/VirtualAtten...
- 👋Attending #ACC2026? Stop by the GARDP virtual booth where you will find useful resources on our programmes, partnerships and platforms by clicking 'Exhibition' tab on the conference site. Take a look👇 portalapp.bsac.eventsair.com/VirtualAtten...
- 🧪✨Now live | Session Two at ACC 2026 From systems views on AMR to novel antibiotics and biofilm control, this session dives into the frontiers of drug discovery. Tune in now. portalapp.bsac.eventsair.com/VirtualAtten... @elisca.bsky.social @ethz.ch @mcmasteruniversity.bsky.social
- 📢🪧Check out the #ACC2026 Poster Gallery! Browse posters, download files and watch author videos clicking the ‘Poster Gallery’ tab at the portal link. Find insights across discovery, clinical work, public health and access. 🔗 portalapp.bsac.eventsair.com/VirtualAtten...
- 🔴 Keynote now live at #ACC2026 Topic: Optimising multinational clinical trials with antimicrobials and the critical role of clinical trial networks 🧬🌍 Featuring Prof David Paterson, National University of Singapore and ADVANCE-ID. 🔗 bit.ly/4rmSteA @advance-id.bsky.social
- 🚀 #ACC2026 kicks off today! This year’s conference is packed with sessions spanning early-stage research, clinical evidence and policy-relevant insights at a critical moment for #AMR. 📌Check the sessions below and register now (if you haven’t already) 🔗 eventsair.pulse.ly/7mo5iqqr5v
- 🎗️ This #WorldCancerDay, we’re highlighting why the future of cancer care depends on the future of antibiotics. Drug-resistant infections already threaten people undergoing cancer treatment. As #AMR rises, progress in cancer care is at risk.
- 📣ACC2026 kicks off tomorrow! Join a global, online and open-access conference our antimicrobial chemotherapy, AMR and the future of antibiotic innovation. 🗓️ 4–5 Feb 2026 | 🌍 Online 🔗 Last chance to register: eventsair.pulse.ly/35puv6u0m6 #ACC2026
- 🤝 GARDP has signed an MoU with Lixa, an emerging biotech based in Western Australia. This MoU establishes a framework to assist LIXA’s preclinical candidate, NeoX-121, a novel unconventional antimicrobial with the potential to become a “resistance breaker”.
- ⏰One week to go until #ACC2026! From early antibiotic discovery to real-world clinical use and access, ACC2026 brings together global expertise for 2 days of focused discussion, live Q&A and shared learning. 📅 4–5 Feb 2026 I🌍Free and Online 🔗 Register now: eventsair.pulse.ly/lvlg78hsiq
- GARDP’s Manica joined MPs from several countries for a luncheon under the Parliamentary Dialogue Programme. Co-hosted by UNITE and the Konrad-Adenauer-Stiftung, it brought together public and private-sector actors, including GSK. @gsk.bsky.social
- 💻Join REVIVE and the CF AMR Syndicate on 19 Feb 2026 for a live webinar on innovation for hard-to-treat cystic fibrosis (CF) infections, with expert insights from clinicians and developers. 🔗Register now: gotowebinar.pulse.ly/hiejrosaq2 @imperialnhli.bsky.social I @janedaviescf.bsky.social
